Last reviewed · How we verify
HL231 Solution for Inhalation — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
HL231 Solution for Inhalation (HL231 Solution for Inhalation) — Haisco Pharmaceutical Group Co., Ltd.. HL231 is an inhaled formulation designed to deliver therapeutic agents directly to the respiratory tract for local and/or systemic effects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HL231 Solution for Inhalation TARGET | HL231 Solution for Inhalation | Haisco Pharmaceutical Group Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HL231 Solution for Inhalation CI watch — RSS
- HL231 Solution for Inhalation CI watch — Atom
- HL231 Solution for Inhalation CI watch — JSON
- HL231 Solution for Inhalation alone — RSS
Cite this brief
Drug Landscape (2026). HL231 Solution for Inhalation — Competitive Intelligence Brief. https://druglandscape.com/ci/hl231-solution-for-inhalation. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab